天山生物(300313) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥16,866,279.73, a decrease of 71.41% compared to the same period last year[5] - The net profit attributable to shareholders was -¥3,902,570.15, representing a 71.70% increase in losses year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥4,108,249.94, a 69.39% increase in losses compared to the previous year[5] - The company reported total operating revenue of ¥58,478,285.53, a decrease of 45% compared to ¥106,287,698.79 in the previous period[46] - The company’s total liabilities decreased to ¥232,942,500.82 from ¥242,514,811.12[44] - The company’s equity attributable to shareholders improved to ¥34,393,812.61 from a negative equity of -¥3,779,268.32[44] - The net profit for the current period is -10,963,990.77, compared to -40,929,503.15 in the previous period, showing an improvement[47] - Basic and diluted earnings per share are both -0.0374, compared to -0.1330 in the previous period[48] - The total operating profit (loss) is -7,578,710.70, an improvement from -35,615,837.42 in the previous period[47] - The company reported a total comprehensive income of -10,963,990.77, compared to -40,929,503.15 in the previous period, indicating a significant reduction in losses[47] Assets and Liabilities - Total assets at the end of the reporting period were ¥277,533,099.71, an increase of 11.82% from the end of the previous year[5] - Current assets totaled ¥95,486,736.89, up from ¥62,540,010.51 at the start of the period[42] - The company's cash and cash equivalents decreased to ¥8,739,557.55 from ¥24,500,019.79[42] - The company’s inventory increased significantly to ¥68,340,601.27 from ¥18,468,103.62[43] - Cash and cash equivalents at the end of the period stand at 8,739,557.55, down from 14,044,848.48 in the previous period, a decrease of approximately 37.5%[49] Cash Flow - The company's cash flow from operating activities showed a net outflow of -¥51,013,529.64, a significant decline of 1,444.49% year-to-date[5] - Cash inflow from operating activities decreased by 40.96% to ¥66,725,423.73, attributed to lower sales revenue from live livestock[13] - Cash flow from operating activities shows a net outflow of -51,013,529.64, a significant decline from a net inflow of 3,794,254.51 in the previous period[48] - Investment activities resulted in a net cash outflow of -846,261.03, compared to a net inflow of 417,117.37 in the previous period[49] - The company raised 40,000,000.00 in cash from borrowings, compared to 122,500,000.00 in the previous period, indicating a decrease of about 67.3%[49] Shareholder Information - Total number of common shareholders at the end of the reporting period is 11,496[15] - The largest shareholder, Xinjiang Tianshan Animal Husbandry Biotechnology Co., Ltd., holds 23.39% of shares, totaling 73,198,402 shares[15] - The second-largest shareholder, Huzhou Haohui Enterprise Management Consulting Co., Ltd., holds 22.11% of shares, totaling 69,211,312 shares[15] - The third-largest shareholder, Chen Dehong, holds 10.95% of shares, totaling 34,279,083 shares, with 33,509,768 shares pledged[15] - Xinjiang Animal Husbandry Group Co., Ltd. holds 10.55% of shares, totaling 33,025,998 shares[15] - The total number of shares held by the top 10 shareholders accounts for a significant portion of the company's equity[15] - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending[15] - There are no preferred shareholders or changes in restricted shares reported for this period[16] - The company has a total of 53,861,312 shares (17.21% of total shares) with voting rights entrusted to Xiamen Shed[15] - The report indicates that there are no significant changes in the status of restricted shares for major shareholders[17] Legal and Strategic Developments - The company is currently involved in multiple legal proceedings regarding the execution of pledged shares, with some cases still under review[31][33][35] - The company plans to liquidate its subsidiary, Ningxia Meijia Agricultural Biotechnology Development Co., Ltd., due to unclear strategic direction and consecutive years of losses[39] Government Subsidies - The company received government subsidies amounting to ¥3,684,506.76, a 573.92% increase compared to the previous year[11] Impairment and Costs - The company recognized an impairment provision of ¥28,690,000 due to changes in the agricultural technology production environment[37] - Total operating costs were ¥71,393,105.79, down 47% from ¥135,898,039.38 in the prior period[46]